ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

0.9369
-0.0131
( -1.38% )
Updated: 10:30:04

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.9369
Bid
0.9275
Ask
0.9499
Volume
79,445
0.9152 Day's Range 0.95
0.6301 52 Week Range 1.58
Market Cap
Previous Close
0.95
Open
0.92
Last Trade
1
@
0.9373
Last Trade Time
10:30:02
Financial Volume
$ 73,881
VWAP
0.929959
Average Volume (3m)
279,022
Shares Outstanding
53,990,294
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-0.98
Revenue
2.43M
Net Profit
-52.67M

About Lucid Diagnostics Inc

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Lucid Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LUCD. The last closing price for Lucid Diagnostics was $0.95. Over the last year, Lucid Diagnostics shares have traded in a share price range of $ 0.6301 to $ 1.58.

Lucid Diagnostics currently has 53,990,294 shares outstanding. The market capitalization of Lucid Diagnostics is $51.29 million. Lucid Diagnostics has a price to earnings ratio (PE ratio) of -0.95.

LUCD Latest News

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 13, 2024 EsoGuard® revenue up 20 percent sequentially Clinical evidence package for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1231-11.61320754721.061.120.90297037561.01084553CS
40.09711.54899392780.83991.120.83464653250.9860211CS
120.095411.33689839570.84151.120.732790220.91138766CS
260.00690.7419354838710.931.120.6812171500.87598695CS
52-0.3731-28.48091603051.311.580.63011777910.94109573CS
156-9.1231-90.686878727610.0610.060.63011302352.01845992CS
260-11.8131-92.651764705912.7513.50.63011391532.82062563CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PRFXPainReform Ltd
$ 1.54
(187.85%)
86.6M
NCNCnoco noco Inc
$ 0.2265
(133.51%)
504.68M
WBUYWeBuy Global Ltd
$ 0.2453
(54.18%)
143.58M
SMCXDefiance Daily Target 2X Long SMCI ETF
$ 38.77
(51.92%)
1.76M
TRNRInteractive Strength Inc
$ 3.58
(41.50%)
21.89M
AKTXAkari Therapeutics PLC
$ 1.56
(-31.88%)
84.34k
DMNDamon Inc
$ 1.7081
(-29.12%)
333.84k
QMMMQMMM Holdings Limited
$ 1.26
(-27.17%)
2.87M
APLMApollomics Inc
$ 0.1469
(-24.20%)
13.01M
WCTWellchange Holdings Company Limited
$ 2.8001
(-19.77%)
256.53k
NCNCnoco noco Inc
$ 0.2288
(135.88%)
504.7M
WBUYWeBuy Global Ltd
$ 0.2514
(58.01%)
144.02M
SMCISuper Micro Computer Inc
$ 27.10
(25.81%)
94.95M
PRFXPainReform Ltd
$ 1.54
(187.85%)
86.6M
NVDANVIDIA Corporation
$ 142.885
(1.95%)
57.13M

LUCD Discussion

View Posts
georgie18 georgie18 1 week ago
LUCD...$1.08...Off my .90 alert...🥳

georgie18

Member Level
Re: georgie18 post# 384972

Thursday, November 07, 2024 8:57:15 AM

Post#
385327
of 385451
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
chemist72 chemist72 2 weeks ago
What is the MoIDX Medicare Program?
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35025
👍️0
georgie18 georgie18 2 weeks ago
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 3 weeks ago
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 3 weeks ago
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
Monksdream Monksdream 8 months ago
LUCD new 52 lo
👍️0
Monksdream Monksdream 1 year ago
LUCD new 52 week low
👍️0
ErnieBilco ErnieBilco 3 years ago
Should have listened to the chart telling me lower but I bought some at $2.39 and $2.21 for a starter. It has a $9+ PT
👍️0
makinezmoney makinezmoney 3 years ago
$LUCD: Not the EV Car Company...............


But you can easily get confused.



Now at $7.30 here in PreMarket



https://www.luciddx.com/





GO $LUCD
👍️0

Your Recent History

Delayed Upgrade Clock